BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 20809904)

  • 1. Infiltrating macrophages in extratumoural tissues after brachytherapy of uveal melanoma.
    Toivonen P; Kivelä T
    Acta Ophthalmol; 2012 Jun; 90(4):341-9. PubMed ID: 20809904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophages and microcirculation in regressed and partially regressed irradiated choroidal and ciliary body melanomas.
    Toivonen P; Mäkitie T; Kujala E; Kivelä T
    Curr Eye Res; 2003 Oct; 27(4):237-45. PubMed ID: 14562175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pigmented episcleral deposits after brachytherapy of uveal melanoma.
    Toivonen P; Kivelä T
    Ophthalmology; 2006 May; 113(5):865-73. PubMed ID: 16530837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of inflammatory cells in uveal melanoma after prior irradiation.
    Vu TH; Bronkhorst IH; Versluis M; Marinkovic M; van Duinen SG; Vrolijk J; Luyten GP; Jager MJ
    Invest Ophthalmol Vis Sci; 2013 Jan; 54(1):360-9. PubMed ID: 23211827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma.
    Mäkitie T; Summanen P; Tarkkanen A; Kivelä T
    Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1414-21. PubMed ID: 11381040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corneoscleral necrosis after episcleral Au-198 brachytherapy of uveal melanoma.
    Chaudhry IA; Liu M; Shamsi FA; Arat YO; Shetlar DJ; Boniuk M
    Retina; 2009 Jan; 29(1):73-9. PubMed ID: 18728617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell proliferation activity in posterior uveal melanoma after Ru-106 brachytherapy: an EORTC ocular oncology group study.
    Pe'er J; Stefani FH; Seregard S; Kivela T; Lommatzsch P; Prause JU; Sobottka B; Damato B; Chowers I
    Br J Ophthalmol; 2001 Oct; 85(10):1208-12. PubMed ID: 11567966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of beta-ray therapy in the treatment of choroidal and ciliary body melanomas].
    Grange JD; Gérard JP; Ragab M; Delaroche G; Jean-Louis B; Bievelez B; Sentenac I; Baute B
    Ophtalmologie; 1989; 3(3):175-9. PubMed ID: 2641104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathologic study of eyes after iodine I 125 episcleral plaque irradiation for uveal melanoma.
    Saornil MA; Fisher MR; Campbell RJ; Robertson DM; Earle JD; Eagle RC; Shields JA; Shields CL; Chandra SR; Albert DM
    Arch Ophthalmol; 1997 Nov; 115(11):1395-400. PubMed ID: 9366669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour cell proliferation after failed ruthenium plaque radiotherapy for posterior uveal melanoma.
    Seregard S; Lundell G; Lax I; af Trampe E; Kock E
    Acta Ophthalmol Scand; 1997 Apr; 75(2):148-54. PubMed ID: 9197561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of M2-macrophages in uveal melanoma and relation with survival.
    Bronkhorst IH; Ly LV; Jordanova ES; Vrolijk J; Versluis M; Luyten GP; Jager MJ
    Invest Ophthalmol Vis Sci; 2011 Feb; 52(2):643-50. PubMed ID: 20811059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma associated spongiform scleropathy: characterization, biochemical and immunohistochemical studies.
    Alyahya GA
    Acta Ophthalmol; 2008 Oct; 86 Thesis 3():1-21. PubMed ID: 18826517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma.
    Mäkitie T; Carpén O; Vaheri A; Kivelä T
    Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2442-9. PubMed ID: 11581181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton beam therapy and iris neovascularisation in uveal melanoma.
    Boyd SR; Gittos A; Richter M; Hungerford JL; Errington RD; Cree IA
    Eye (Lond); 2006 Jul; 20(7):832-6. PubMed ID: 16167079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruthenium-106 plaque brachytherapy for thick posterior uveal melanomas.
    Kaiserman N; Kaiserman I; Hendler K; Frenkel S; Pe'er J
    Br J Ophthalmol; 2009 Sep; 93(9):1167-71. PubMed ID: 19570767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
    Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S
    Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [High-dose 106Ruthenium plaque brachytherapy for posterior uveal melanoma. A clinico-pathologic study].
    Heindl LM; Lotter M; Strnad V; Sauer R; Naumann GO; Knorr HL
    Ophthalmologe; 2007 Feb; 104(2):149-57. PubMed ID: 17123048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PC-10 immunostaining of proliferating cell nuclear antigen in posterior uveal melanoma. Enucleation versus enucleation postirradiation groups.
    Pe'er J; Gnessin H; Shargal Y; Livni N
    Ophthalmology; 1994 Jan; 101(1):56-62. PubMed ID: 7905616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of histo-pathologic examination of three enucleated eyes with a choroidal melanoma after strontium-90 irradiation.
    Parys-van Ginderdeuren R; van den Oord JJ; Missotten L
    Bull Soc Belge Ophtalmol; 1997; 265():47-54. PubMed ID: 9479819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ki-67 immunostaining in uveal melanoma. The effect of pre-enucleation radiotherapy.
    Mooy CM; de Jong PT; Van der Kwast TH; Mulder PG; Jager MJ; Ruiter DJ
    Ophthalmology; 1990 Oct; 97(10):1275-80. PubMed ID: 2243677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.